ABVX:EPA
Abivax SA
77,15 €
arrow_downward
-0,64%(-0,50) 1D
6 қар., 17:36:06 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ABVX...
Open
74,45 €
High
77,15 €
Low
73,80 €
Mkt. cap
6,84 млрд
Avg. vol.
111,44 м.
Volume
161,37 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
Open
74,45 €
High
77,15 €
Low
73,80 €
Mkt. cap
6,84 млрд
Avg. vol.
111,44 м.
Volume
161,37 м.
52-wk high
139,00 €
52-wk low
60,45 €
EPS
-5,20 €
Shares outstanding
87,55 млн
No. of employees
98
News stories
From web sources and news partners
Quantisnow
·
11 минут бұрын
Tech Lifts Nasdaq 100 1.27% While Dow and Equal-Weight Slip
TradingKey
·
13 минут бұрын
S&P 500 Sees Nearly Zero Gains in Five Months: Valuation Drops to 18.5 Times, Are US Stocks Getting Cheaper?
TradingView
·
1 сағат бұрын
Nasdaq rebounds but posts fourth straight weekly decline
Investor's Business Daily
·
1 сағат бұрын
Futures: Market Needs Repair; These Big Winners Are Broken
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
About Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Employees98
Founded2013 ж. 04 жел.
Headquarters-
SectorHealth Care
Industry-
Websiteabivax.com